Ask AI
Advances and Challenges in RR B ALL

CME

Clinical Advances in Immune-Engager Therapies for the Treatment of Relapsed/Refractory B-ALL

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 29, 2026

Expiration: October 28, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2006;109:944-950.
  2. Tavernier E, Boiron J-M, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907-1914.
  3. Gökbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101:1524-1533.
  4. Blinatumomab [package insert]. Thousand Oaks, CA: Amgen Inc.; 2020.
  5. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836-847.
  6. Gökbuget N, Zugmaier G, Dombret H, et al. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61:2665-2673.
  7. Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320-333.
  8. van der Sluis I, de Lorenzo P, Kotecha RS, et al. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023;388:1572-1581.
  9. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57-66.
  10. Aldoss I, Otoukesh S, Zhang J, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022;128:529-535.
  11. Aldoss I, Li S, Zhang J, et al. TP53 mutations are associated with CD19− relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025;9:2159-2172.
  12. Jabbour E, Rambaldi A, Martίnez-Sάnchez P, et al. Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): results from a phase 1/2 dose expansion study. Presented at: 2025 European Hematology Association Annual Conference; June 12-15, 2025. Abstract S112.
  13. Tisagenlecleucel [prescribing information]. Basel, Switzerland: Novartis; 2017.
  14. Brexucabtagene autoleucel [prescribing information]. Santa Monica, CA: Kite Pharma, Inc.; 2021.
  15. Obecabtagene autoleucel [prescribing information]. White City, London: Autolus Therapeutics; 2024.
  16. Muhsen IN, Roloff GW, Faramand R, et al. Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025;9:4081-4089.
  17. Trinklein ND, Pham D, Schellenberger U, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. MAbs. 2019;11:639-652.
  18. Aldoss I, Yoon J-H, Barba P, et al. Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: early results from the phase 1/2 SYRUS study. Presented at: 2025 European Hematology Association Annual Conference; June 12-15, 2025. Abstract S117.
  19. Wang Y, Yin Q, Ren J, et al. Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Presented at: 2024 American Society of Clinical Oncology Annual Conference; May 31 - June 4, 2024. Abstract 6505.
  20. Xie Y, Cai Q, Liu H, et al. Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Presented at: 2024 American Society of Clinical Oncology Annual Conference; May 31 - June 4, 2024. Abstract 7040.
  21. Wang Y, Yin Q, Ren J, et al. Updated results from the phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia. Presented at: 2025 American Society of Hematology Annual Conference; December 6-9, 2025. Abstract 647.
  22. National Comprehensive Cancer Network. NCCN guidelines: management of CAR T-cell and lymphocyte engager-related toxicities. v.2.2026. nccn.org. Accessed April 27, 2026.